Please replace claims 2, 5, 9-10, 15-16 and 24-26 as follows:

2. (Twice Amended) The method of claim 12 where the harringtonine is homoharringtonine or harringtonine having the following formula

B1



where n = 2 or 3.

5. (Twice Amended) The method of claim 12 in which the harringtonines are solutions or hydrophilic freeze-dried powder ready-to-constitute of buffered salt of homoharringtonine or harringtonine of which the level of chromatographic purity suitable for medical use is higher than 99.7%.

B2

9. (Twice Amended) The method of therapy of claim 12 in which the subcutaneous mode of administration is performed by bolus injection at regular intervals.

B3

10. (Twice Amended) The method of claim 12 in which the subcutaneous mode of administration is performed by continuous subcutaneous infusion.

15. (Amended) The method of claim 12 where the harringtonine is a harringtonine salt having the following formula



where A^{p-} is

a mineral anion selected from the group consisting of chloride, sulfate, nitrate, and perchlorate, or

an organic ion selected from the group consisting of tartarate, malate, lactate, and citrate, and p is 1 or 2

and R^1, R^2, R^3, R^4, R^5, R^7, R^8 and n are as defined in claim 12.

16. (Twice Amended) The method of claim 12 where the harringtonine is a harringtonine salt having the following formula



where A^{p-} is

a mineral anion selected from the group consisting of chloride, sulfate, nitrate, and perchlorate, or

an organic ion selected from the group consisting of tartarate, malate, lactate, and citrate, and p is 1 or 2

and n is as defined in claim 12.

24. (Amended) The method of claim 12, wherein the cancer to be treated is a lymphoma.

25. (Amended) The method of claim 12, wherein said patient is a human.

26. (Amended) The method of claim 12, wherein said patient is an animal.

Please add new claims 28-30 as follows.

--28. (New) A method of treating leukemia comprising administering to a patient in need of such treatment using a subcutaneous mode of administration a harringtonine salt or tautomeric form thereof, wherein the harringtonine has the formula



wherein:

- R^1 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or null and

  R^2 is H or OH, or R^1, R^2 form together -O-,

  R^3 = R^4 = OMe or R^3 and R^4 form together -OCH_2O-,
- n is 0 to 8,
- R^5 is H, OH, OMe, O-(C_1-C_{30})-alkyl, O-aryl-(C_1-C_{30})-alkyl, O-(C_2-C_{30})-alkenyl, O-(C_3-C_{30})-cycloalkyl or O-aryl,

Z = O, S, or NH, and

$$R^8 = \begin{array}{l} R^9 \\ \diagup \\ \text{—} \\ \diagdown \\ R^{10} \\ R^{11} \end{array}$$

or Z-R^8 is $NR^{12}R^{13}$, R^{12} and R^{13} representing respectively R^9 and R^{10},

R^9, R^{10}, R^{11} are independently H, C_1-C_{30} alkyl, C_3-C_{30} clcloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl, C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, C_1-C_{30} alkylamino-(C_1-C_{30})alkyl, C_1-C_{30} dialkylamino(C_1-C_{30})-alkyl, or amino-(C_1-C_{30})-alkyl, or

$$\begin{array}{l} R^{14} \quad R^{15} \\ \diagup \quad \diagdown \\ \text{—}(CH_2)_m \quad R^{16} \end{array}$$

where R^{14}, R^{15}, R^{16} are independently H, halogen, C_1-C_{30} alkyl, C_3-C_{30} cycloalkyl, aryl, aryl-(C_1-C_{30})-alkyl, C_2-C_{30} alkenyl or C_2-C_{30} alkynyl, C_1-C_{30} trihalogenoalkyl, m is 0 to 4,

each of these groups optionally including heteroatom(s),

wherein said harringtonine is in a formulation in which

(i) the pH of the formulation is between 5.5 and 8.5,

(ii) the harringtonines are in solution or hydrophilic freeze-dried powder ready-to-reconstitute of buffered salt of homoharringtonine or harringtonine, and

(iii) the level of chromatographic purity of harringtonine is higher than 99.7%.

29. (New) The method of claim 28 where the harringtonine is a harringtonine salt having the following

formula



where A^{p-} is

a mineral anion selected from the group consisting of chloride, sulfate, nitrate, and perchlorate, or

an organic ion selected from the group consisting of tartarate, malate, lactate, and citrate, and p is 1 or 2

and R^1, R^2, R^3, R^4, R^5, R^7, R^8 and n are as defined in claim 28.

30. (New) The method of claim 28 where the harringtonine is a harringtonine salt having the following formula



where A^{p-} is

a mineral anion selected from the group consisting of chloride, sulfate, nitrate, and perchlorate, or

an organic ion selected from the group consisting of tartarate, malate, lactate, and citrate, and p is 1 or 2

and n is as defined in claim 28.--